Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche to name a new CEO by March 2023

<< Previous

Bullboard Posts

Next >>

Comment by itntdfon Feb 08, 2023 2:33pm

124 Views

Post# 35275135

RE:RE:RE:RE:RE:RE:RE:Roche to name a new CEO by March 2023

again, how did AN "clear the way"?

ANY approved use of pela with any other "agent" in AN's territory benefits AN with a double digit royalty going to oncy or its successor. any big pharma that wants to obtain approval for ANYTHING using pela in AN's territory is limited by the AN agreement and would be settling for a double digit royalty.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec